Prøve GULL - Gratis
India Announces Major Tax Cuts To Boost Investment
Bio Spectrum
|November 2019
USV Private Limited, an Indian multinational pharmaceutical, and biotechnology company based in Mumbai reacting quickly to the developments and leveraging on the government’s surprise corporate tax rate cut on September 20 announced that it will proceed with its investment of Rs 400 crore on a new state-of-art formulation plant at Vadodara in Gujarat.
-

The company noted that the announcement by the government has provided the much-needed boost to the pharmaceutical manufacturing sector that requires investments to provide world-class medicines to the population, at large. While the tax cut announced by the government will increase capital spending and generate employment in the pharmaceutical sector, these investments will also go a long way to improve sustainability and capacities in pharmaceutical manufacturing.
In order to promote growth and investment in India, the Union Minister for Finance & Corporate Affairs Nirmala Sitaraman announced that the Government of India has brought in the Taxation Laws (Amendment) Ordinance 2019 to make certain amendments in the Income-tax Act 1961 and the Finance (No. 2) Act 2019.
The Finance Minister said “a new provision has been inserted in the Income-tax Act with effect from FY 2019-20 which allows any domestic company an option to pay income-tax at the rate of 22% subject to the condition that they will not avail any exemption/ incentive. The effective tax rate for these companies shall be 25.17% inclusive of surcharge & cess. Also, such companies shall not be required to pay Minimum Alternate Tax (MAT).”
She also noted that in order to attract fresh investment in manufacturing and thereby provide boost to ‘Make-in-India’ initiative of the government, another new provision has been inserted in the Income-tax Act with effect from FY 2019-20 which allows any new domestic company incorporated on or after October 1, 2019 making fresh investment in manufacturing, an option to pay income-tax at the rate of 15%. This benefit is available to companies that do not avail of any exemption/incentive and commences their production on or before March 31, 2023. The effective tax rate for these companies shall be 17.01% inclusive of surcharge & cess. Also, such companies shall not be required to pay MAT.
Denne historien er fra November 2019-utgaven av Bio Spectrum.
Abonner på Magzter GOLD for å få tilgang til tusenvis av kuraterte premiumhistorier og over 9000 magasiner og aviser.
Allerede abonnent? Logg på
FLERE HISTORIER FRA Bio Spectrum

Bio Spectrum
Navigating the Complexities of Pharma Packaging Sustainability
Pharma companies in India are increasingly adopting sustainable methods in packaging to ensure that medicines remain safe and the environment is protected. Various initiatives by the government, focusing on reducing carbon footprints, are revolutionising the pharma packaging industry.
8 mins
September 2025

Bio Spectrum
Are BioStartUps in a Funding/Innovation Rut?
At the BioStartUps Founders & Investors Forum 2025, held on August 1, 2025 at the CIDCO Exhibition Centre in Vashi, Navi Mumbai, biotech industry stalwarts deliberated on the country's innovation and startup ecosystem.
10 mins
September 2025

Bio Spectrum
How Do Recent Deaths Impact Gene Therapy Development?
Cell and gene therapy (CGT) is among the most closely watched areas in pharma and biotech.
4 mins
September 2025

Bio Spectrum
HealthQuad appoints Namit Chugh as Director
Quadria Group, Asia's leading healthcare-focused private equity platform, has announced the appointment of Namit Chugh as Director at HealthQuad, India's leading healthcare-focused growth venture capital platform.
1 min
September 2025

Bio Spectrum
Why Is Endoscopy Crucial for Gl Cancer Diagnosis?
The increased demand for gastrointestinal (GI) diagnostics in India, driven by rising disease rates and awareness of early intervention, is not evenly distributed. While major urban hospitals have expanded their endoscopic capabilities, many semi-urban and rural areas face limited access. Addressing this disparity is crucial for extending the benefits of early disease detection across the country.
4 mins
September 2025
Bio Spectrum
New England Biolabs launches NEBNext low-bias small RNA library prep kit
US-based New England Biolabs (NEB) has announced the launch of the NEBNext Low-bias Small RNA Library Prep Kit, designed to minimise biased representation of small RNA species in sequencing data.
1 min
September 2025

Bio Spectrum
Qiagen expands NGS portfolio with launch of QIAseq XHYB long read panels
Qiagen has announced the launch of its new QIAseq xHYB Long Read Panels, a suite of target enrichment solutions designed to unlock long-read sequencing of genomically complex regions.
1 min
September 2025

Bio Spectrum
"Awareness and consistent training are needed with the growing demand for effective skin treatments in India"
India’s dermatology and aesthetic market is reportedly among the fastest-growing globally, projected to grow at a CAGR of 10.11 per cent from 2025 to 2032.
4 mins
September 2025
Bio Spectrum
Dr. Moopen's Legacy Scholarship & Fellowships to aid 25 students from across India
In a path breaking initiative to make medical education accessible to meritorious students and students from economically challenged backgrounds, Padma Shri Dr Azad Moopen, Founder & Chairman of Aster DM Healthcare and a globally recognised philanthropist, has announced an annual scholarship programme Dr. Moopen's Legacy Scholarship & Fellowships Programme aimed at supporting meritorious students seeking admissions in Dr. Moopen's Medical College, Dr Moopen's Nursing College and Dr Moopen's College of Pharmacy in Wayanad, Kerala.
1 min
September 2025

Bio Spectrum
Iberia Pharma set to open manufacturing unit in India with investment of Rs 70 Cr
Gurugram-based Iberia Pharmaceuticals has announced its new hi-tech manufacturing and research facility spread across 60,000 sq. ft. in Jhajjar, Haryana.
1 min
September 2025
Translate
Change font size